3741.9000 11.30 (0.30%)
NSE Jul 31, 2025 15:31 PM
Volume: 261.7K
 

Motilal Oswal
Margins expand; Improvement in US business remains key TRP reported sales of INR14.3b (+4.5% YoY; ~5% miss) in 3QFY18. The miss on revenue can be attributed to a decline in the US and Brazilian businesses. India business grew 22% YoY to INR6.1b (~23% growth adj. for GST). EBITDA increased 14% YoY to INR3.53b (est. of INR3.62b). Margin expanded ~195bp YoY (+130bp QoQ), primarily due to a favorable product mix toward higher-margin branded products. PAT declined 72% YoY to INR580m, mainly due to a one-time impact of the Unichem acquisition and the re-measurement of deferred tax on account...
ICICI Securities Limited increased Hold price target of Torrent Pharmaceuticals Ltd. to 3530.0 on 29 Jul, 2025.
More from Torrent Pharmaceuticals Ltd.
Recommended